Sir,

The association of acute myeloid leukemia (AML) with plasmacytosis is a known, although rare event. There are very few case reports documenting an increase in the number of plasma cells at the time of AML diagnosis. Paracrine interleukin-6 production by leukemic blast cells is thought to contribute to this associated reactive plasma cell proliferation.

Plasmacytosis is known in acute myeloid leukemia bone marrows undergoing remission after chemotherapy. However plasmacytosis presenting at the time of AML diagnosis is relatively rare. An exuberant proliferation of plasma cells on bone marrow examination masking the exact percentage of blasts can easily be confused with plasma cell dyscrasias.

Reactive plasmacytosis characterized by a diffuse distribution of mature plasma cells in the bone marrow is known to occur in inflammatory conditions (bacterial and viral infections, collagen vascular diseases, granulomatous diseases, rheumatic heart disease), in liver cirrhosis and as a paraneoplastic syndrome in various neoplasms such as Hodgkin’s disease, non-Hodgkin’s lymphomas, carcinomas, and in AML patients undergoing induction chemotherapy.

Cases of AML that have a high plasma cell count can present as diagnostic dilemmas and should always be subjected to further sophisticated investigations before a diagnosis is given based only on morphology. Morphological features suggesting a reactive nature of plasma cells, although not specific, are mature forms of plasma cells, perivascular location of plasma cells and plasmacytic satellitosis (orientation of plasma cells around histiocytes).

Few cases have been reported in the literature where plasmacytosis is seen with AML at the time of diagnosis. In these cases, plasma cells usually do not exceed 10%. However, there are very few cases where the plasma cell count is found to be higher than 20% in newly diagnosed acute leukemias. In a study by Rosenthal et al., 149 cases of AML were studied at the time of diagnosis, with only two cases showing a plasma cell count of more than 20%.

The etiology of reactive bone marrow plasmacytosis is supposed to be a physiological response to antigenic stimulation. Although mediation by a paracrine growth factor originating from the leukemic cells is possible, the mechanism of this bone marrow plasmacytosis has not yet been addressed. Interleukin (IL)-6 production by the AML blasts may play a pivotal role in the growth of the plasma cells. For a definitive estimation of the role of IL-6 in AML-associated plasmacytosis, a larger cohort of patients should be analyzed.

References

* Corresponding author.
E-mail address: iffjamal1111@gmail.com (I. Jamal).
2. Liu CT, Dahlke MB. Bone Marrow Findings of Reactive Plasmacytosis. 


4. Al-Shughair N, Al-Dawsari G, Gyger M, Mohamed G, Roberts G. Clinical significance of plasmacytosis in the day+14 bone 
   marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy. 

   myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells. 


**Author biography**

Iffat Jamal, Assistant Professor

---

Cite this article: Jamal I. Florid plasmacytosis in cases of acute myeloid leukemia: A diagnostic dilemma. 